ArticleProceedings of the National Academy of Sciences of the United States of America2026
ADAR-GPT: A continually fine-tuned language model for predicting A-to-I RNA editing sites.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structure-aware graph learning predicts RNA editability across tissues and species.Research square · 2026Article
- ADAR-GPT: Learning the language of the epitranscriptome.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
Adenosine-to-inosine (A-to-I) RNA editing by ADAR enzymes shapes transcript fate and underpins emerging RNA editing therapeutics, yet predicting which adenosines are edited remains difficult. We introduce ADAR-GPT, a model-agnostic fine-tuning framework that adapts a GPT-class language model to classify editing at candidate sites using sequence context in standardized 201 nt windows with the target adenosine explicitly marked. We train and evaluate on GTEx liver data ([Formula: see text] samples) at a clinically relevant 15% editing threshold, using a two-stage continual fine-tuning approach where lower thresholds serve as curriculum data to progressively sharpen decision boundaries. Using sequence data, ADAR-GPT demonstrates competitive or superior performance when benchmarked against established computational approaches, including convolutional and foundation model architectures, achieving a better balance of recall, precision, and specificity alongside stronger operating-curve metrics. The approach is reproducible and portable across GPT backbones without architectural changes. Beyond accurate site classification, ADAR-GPT provides practical adenosine scoring to prioritize experimental targets and inform guide RNA design, with a framework adaptable to new datasets and model architectures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.